Lv04
0 积分 2024-09-05 加入
Proteomic screening identifies PF4/Cxcl4 as a critical driver of myelofibrosis
2小时前
已完结
Fibroblast and myofibroblast activation in normal tissue repair and fibrosis
2小时前
已完结
Myelofibrosis management in routine clinical practice with a focus on patients with cytopenias: recommendations from a global consensus group
8小时前
已完结
Disease Modification in Myelofibrosis: An Elusive Goal?
8小时前
已完结
Myelofibrosis: best practices, controversies and 2019 update
17小时前
已完结
Understanding deregulated cellular and molecular dynamics in the haematopoietic stem cell niche to develop novel therapeutics for bone marrow fibrosis
17小时前
已完结
Evolution of myelofibrosis in chronic idiopathic myelofibrosis as evidenced in sequential bone marrow biopsy specimens
1天前
已完结
Myelofibrosis progression grading based on type I and type III collagen and fibrillin 1 expression boosted by whole slide image analysis
1天前
已完结
A first-in-class JAK/ROCK inhibitor, Rovadicitinib in patients with myelofibrosis who were refractory or relapsed or intolerant to Ruxolitinib: A single-arm, multicenter, open-label, phase Ib study
1天前
已完结
799MO The primary results from a randomized double-blind phase II study of rovadicitinib versus hydroxyurea in patients with myelofibrosis
1天前
已完结
皖公网安备34019202002308
